Tiziano Barbui MD

Tiziano Barbui graduated at the University of Padua (Italy). He was a Consultant in Hematology at San Bortolo Hospital in Vicenza and founded the Department of Hematology at “Ospedali Riuniti di Bergamo” where he was the Director from 1981 to 2008 and chief of the department of Oncology and Hematology. He was an adjunct professor in the school of specialization in hematology of the Universities of Milan (State and Bicocca University) and Verona University.

Professor Barbui is currently the Scientific Director of the FROM Research Foundation at Papa Giovanni XXIII Hospital, Bergamo (Italy). He has served as Chairman of the Subcommittee on Lupus Anticoagulants of the International Society of Thrombosis and Haemostasis and was former President of the Italian Society of Hematology.

Currently, he leads the European-Leukemia-Net WP-9 on Myeloproliferative Disorders. He is one of the founders of the NIH (US) Myeloproliferative Disorders Consortium. Currently, he is a member of the Good Governance Committee of the European Hematology Association (EHA).

Professor Tiziano Barbui published so far more than 700 scientific articles in International peer-reviewed journals. During decades he significantly contributed to many fields of general hematology. The most cited articles refer to the Lupus anticoagulant syndrome, the hemostatic disturbances and therapy of acute leukemia, and the optimization of diagnosis, prognosis, and treatment of myeloproliferative neoplasms. he is one of the principal promoters of European LeukemiaNet guidelines on MPN.

He has been the principal investigator in several academic clinical trials published in the New England Journal of Medicine.
Prof. Barbui received the gold medal from the Bergamo City Hall for his continued dedication to the care of patients with malignant hematologic diseases and his contribution to the advancement of hematology science. During the European Hematology Association (EHA) meeting in Stockholm.

(2013), he received the “Jean-Bernard Award” for his contribution to the optimization of diagnosis, prognosis, and therapy of Myeloproliferative neoplasms and for establishing international networks for clinical research in Hematology. He is currently very involved in research of MPN and COVID on behalf of European Leukemia Net (ELN) and in Polycythemia Vera Clinical Trials.